doi:10.16150/j.1671-2870.2020.02.019

Abstract

CLC Number:

R551.3

References 25

[1]	Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias[J]. Cancer Res, 2010, 70(2):447-452. doi: 10.1158/0008-5472.CAN-09-3783 pmid: 20068184
[2]	Wang S, Yan J, Zhou G, et al. Myeloproliferative neoplasm or reactive process? A rare case of acute myeloid leukemia and transient posttreatment megakaryocytic hyperplasia with JAK-2 mutation[J]. Case Rep Hematol, 2016, 2016:6054017.
[3]	Seavey MM, Dobrzanski P. The many faces of Janus kinase[J]. Biochem Pharmacol, 2012, 83(9):1136-1145. doi: 10.1016/j.bcp.2011.12.024 URL
[4]	Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain[J]. Mol Biol Cell, 2003, 14(4):1448-1459. pmid: 12686600
[5]	Lee HJ, Daver N, Kantarjian HM, et al. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia[J]. Clin Cancer Res, 2013, 19(2):327-335. doi: 10.1158/1078-0432.CCR-12-2087 URL
[6]	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders[J]. N Engl J Med, 2005, 352(17):1779-1790. doi: 10.1056/NEJMoa051113 URL
[7]	成志勇, 黄月华, 梁文同, 等. 骨髓增殖性肿瘤中JAK2 V617F突变与Ⅰ型细胞因子受体相关性研究[J]. 中国全科杂志, 2012, 15(9):1019-1022.
[8]	陈秀花, 王宏伟, 覃艳红, 等. JAK2 V617F阴性真性红细胞增多症患者JAK2 exon 12的突变研究[J]. 中华内科杂志, 2010, 49(9):797-798.
[9]	Lundberg P, Takizawa H, Kubovcakova L, et al. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F[J]. J Exp Med, 2014, 211(11):2213-2230. doi: 10.1084/jem.20131371 URL
[10]	Medinger M, Skoda R, Gratwohl A, et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status[J]. Br J Haematol, 2009, 146(2):150-157. doi: 10.1111/j.1365-2141.2009.07726.x URL
[11]	Nunes DP, Lima LT, Chauffaille Mde L, et al. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients[J]. Blood Cells Mol Dis, 2015, 55(3):236-240. doi: 10.1016/j.bcmd.2015.07.005 URL
[12]	Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproli-ferative disorders are frequently negative for the JAK2-V617F mutation[J]. Blood, 2007, 110(1):375-379. doi: 10.1182/blood-2006-12-062125 pmid: 17363731
[13]	Aynardi J, Manur R, Hess PR, et al. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group[J]. Br J Haematol, 2018, 182(1):78-85. doi: 10.1111/bjh.15276 URL
[14]	Scott LM, Rebel VI. JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?[J]. Am J Hematol, 2012, 87(11):1028-1036. doi: 10.1002/ajh.23243 URL
[15]	Benton CB, Boddu PC, DiNardo CD, et al. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia[J]. Cancer, 2019, 125(11):1855-1866. doi: 10.1002/cncr.31986 URL
[16]	Marty C, Saint-Martin C, Pecquet C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors[J]. Blood, 2014, 123(9):1372-1383. doi: 10.1182/blood-2013-05-504555 URL
[17]	Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative di-sorders[J]. Blood, 2008, 112(4):1402-1412.
[18]	宗香萍, 汤林, 岑建农, 等. 异基因造血干细胞移植治疗原发性血小板增多症转化的急性髓系白血病三例报告并文献复习[J]. 中华血液学杂志, 2017, 38(10):883-886.
[19]	Vicente C, Vázquez I, Marcotegui N, et al. JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers[J]. Leukemia, 2007, 21(11):2386-2390. pmid: 17581610
[20]	沈益民, 晁红颖, 张日, 等. 80例急性髓性白血病M₂型患者JAK2 V617F基因突变的检测及临床意义[J]. 中华肿瘤杂志, 2009, 31(5):366-370.
[21]	禹文君, 陈丽娟, 李建勇, 等. JAK2 V617F突变阳性原发性血小板增多症转化为JAK2 V617F突变阴性急性髓系白血病一例报告并文献复习[J]. 中华血液学杂志, 2014, 35(12):1122-1123.
[22]	Celgene Corporation. INREBIC® (fedratinib) capsules, for oral use: US prescribing information[R/OL]. 2019-08-16[2020-01-13]. http://www.fda.gov/.
[23]	Celgene Corporation. U.S. FDA approves INREBIC® (fedratinib) as frst new treatment in nearly a decade for patients with myelofbrosis[R/OL]. 2019-08-16[2020-01-13]. http://ir.celgene.com.
[24]	Sun J, Du Y, Zhang X, et al. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3[J/OL]. Invest New Drugs, 2019-10-14[2020-01-13]https://www.ncbi.nlm.nih.gov/pubmed/31612426.
[25]	Takagi S, Masuoka K, Uchida N, et al. Allogeneic hematopoietic cell transplantation for leukemic transformation preceded by philadelphia chromosome-negative myeloproliferative neoplasms: A nationwide survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation[J]. Biol Blood Marrow Transplant, 2016, 22(12):2208-2213. doi: 10.1016/j.bbmt.2016.09.017 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 25

Related Articles 10

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(06): 685-671.
[2]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 468-471.
[3]	CAO Yafeng, WANG Jing, GU Jun, LU Hongyu, XUN Jie, LIU Yuanfang, WANG Yan, WANG Jin, CHEN Yu, CHEN Yubao, LI Jiaming, HAO Jie, MI Jianqing, CHEN Mei. Analysis of peripheral neuropathy following treatment with bortezomib in 114 newly-diagnosed multiple myeloma patients [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 492-497.
[4]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 455-459.
[5]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 472-476.
[6]	. [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 545-549.
[7]	. [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 556-560.
[8]	. [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 561-566.
[9]	. [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 567-572.
[10]	. [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 573-577.